TP53 and breast carcinoma: Further, immunoreactivity for p53 in primary breast carcinomas, using antibodies pAb240 and pAb1801, is associated with increased risk for subsequent brain metastasis (Tham et al, 2006), consistent with a potential role for TP53 mutation in CNS metastasis.